WINTON GROUP Ltd Invests $11.12 Million in Charles River Laboratories Intl. Inc (CRL)

Share on StockTwits

WINTON GROUP Ltd bought a new position in Charles River Laboratories Intl. Inc (NYSE:CRL) during the 3rd quarter, HoldingsChannel reports. The fund bought 82,626 shares of the medical research company’s stock, valued at approximately $11,117,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Cadence Capital Management LLC lifted its position in Charles River Laboratories Intl. by 7.1% during the third quarter. Cadence Capital Management LLC now owns 13,142 shares of the medical research company’s stock valued at $1,768,000 after purchasing an additional 873 shares during the period. CIBC Asset Management Inc bought a new position in Charles River Laboratories Intl. during the third quarter valued at approximately $226,000. Cambridge Investment Research Advisors Inc. bought a new position in Charles River Laboratories Intl. during the third quarter valued at approximately $1,281,000. Wells Fargo & Company MN lifted its position in Charles River Laboratories Intl. by 5.9% during the third quarter. Wells Fargo & Company MN now owns 1,394,064 shares of the medical research company’s stock valued at $187,556,000 after purchasing an additional 77,429 shares during the period. Finally, Monarch Partners Asset Management LLC bought a new position in Charles River Laboratories Intl. during the third quarter valued at approximately $14,587,000. Hedge funds and other institutional investors own 96.93% of the company’s stock.

Shares of CRL stock opened at $136.45 on Friday. Charles River Laboratories Intl. Inc has a 12 month low of $96.70 and a 12 month high of $138.89. The company has a market cap of $6.54 billion, a price-to-earnings ratio of 25.89, a price-to-earnings-growth ratio of 1.71 and a beta of 0.74. The company has a debt-to-equity ratio of 1.52, a current ratio of 1.72 and a quick ratio of 1.48.

Charles River Laboratories Intl. (NYSE:CRL) last announced its earnings results on Wednesday, November 7th. The medical research company reported $1.53 EPS for the quarter, beating the Zacks’ consensus estimate of $1.38 by $0.15. Charles River Laboratories Intl. had a net margin of 6.39% and a return on equity of 25.81%. The business had revenue of $585.30 million during the quarter, compared to analysts’ expectations of $567.58 million. During the same period in the prior year, the company earned $1.30 earnings per share. The firm’s revenue was up 26.1% on a year-over-year basis. As a group, research analysts predict that Charles River Laboratories Intl. Inc will post 5.93 earnings per share for the current year.

A number of research analysts recently weighed in on CRL shares. Bank of America increased their price objective on shares of Charles River Laboratories Intl. from $120.00 to $125.00 and gave the company a “buy” rating in a research report on Monday, July 16th. Royal Bank of Canada upgraded shares of Charles River Laboratories Intl. from a “sector perform” rating to an “outperform” rating and set a $131.00 price objective on the stock in a research report on Tuesday, July 17th. ValuEngine upgraded shares of Charles River Laboratories Intl. from a “hold” rating to a “buy” rating in a research report on Wednesday, July 18th. Jefferies Financial Group restated a “buy” rating and set a $140.00 price objective on shares of Charles River Laboratories Intl. in a research report on Friday, July 20th. Finally, SunTrust Banks increased their price objective on shares of Charles River Laboratories Intl. to $135.00 and gave the company a “buy” rating in a research report on Thursday, August 9th. Eight investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Charles River Laboratories Intl. has a consensus rating of “Buy” and an average target price of $130.56.

In other news, insider David Ross Smith sold 1,249 shares of the stock in a transaction on Monday, August 13th. The shares were sold at an average price of $120.05, for a total value of $149,942.45. Following the completion of the sale, the insider now directly owns 13,690 shares of the company’s stock, valued at $1,643,484.50. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider David P. Johst sold 23,356 shares of the stock in a transaction on Wednesday, November 7th. The stock was sold at an average price of $136.00, for a total transaction of $3,176,416.00. Following the completion of the sale, the insider now directly owns 219,849 shares of the company’s stock, valued at $29,899,464. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 28,671 shares of company stock valued at $3,829,160. 2.10% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION NOTICE: This piece was originally posted by Week Herald and is the property of of Week Herald. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this piece can be read at https://weekherald.com/2018/11/10/winton-group-ltd-invests-11-12-million-in-charles-river-laboratories-intl-inc-crl.html.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Further Reading: Growth Stocks, What They Are, What They Are Not

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories Intl. Inc (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply